ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 633

Improvement of Joint Inflammation As Assessed By MRI and Power Doppler Ultrasound (PDUS) in an Open Label Study in Patients with Active Psoriatic Arthritis Treated with Secukinumab.

Eleni Kampylafka1, Isabelle Oliveira1, Christina Linz2, Veronika Lerchen1, Matthias Englbrecht1, Michael Sticherling3, Arnd Kleyer1, Juergen Rech1, Georg Schett1 and Axel J. Hueber1, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, 2Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, e, Germany, 3Department of Dermatology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: MRI, Psoriatic arthritis and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Secukinumab, an anti-interleukin 17A monoclonal antibody, showed significant improvement of signs and symptoms of psoriatic arthritis (PsA) in phase 3 studies. Available studies used conventional radiography, not allowing a deeper imaging analysis of the inflammatory changes during application. The aim of this study was to assess short term efficacy of secukinumab on inflammation and structural damage according to change in OMERACT-EULAR ultrasound score, the MRI PsAMRIS score, and HRpQCT scans of the MCP and PIP joints in PsA patients.

Methods:

PsA patients with active disease (TJC and SJC ≥ 3), were included in the 24 week open label prospective PSARTROS study and treated with subcutaneous secukinumab 300 mg once weekly over 4 weeks, then once every 4 weeks. Baseline 1,5T MRI hand scans, HRpQCT scans of the MCP and PIP joints, and ultrasound imaging of 28 joints were performed at baseline and after 24 weeks of treatment. MRI was scored according to PsAMRIS. HRpQCT scans were evaluated for erosions and osteo-proliferation. Ultrasound was assessed for synovial hypertrophy and Doppler activity according to OMERACT scores. Statistical significance was set at p≤0.05.

Results: 20 patients, mean age 52 ± 9.9 years, 60% female, mean disease duration 6.7 ± 5.9 years, 50% naive for biological therapy, were included in the study. Three patients were early discontinued (recurrent pharyngitis, lack of efficacy, withdrawal of consent), and were not included into the longitudinal analysis. Baseline DAS28 was 5.03±0.96, baseline DAPSA was 32.2±12. 1. On baseline MRI, all patients had at least one inflammatory sign (synovitis: 90%, osteitis: 20%, periarticular inflammation: 25%, flexor tenosynovitis: 35%, bone proliferation: 30%, erosions: 60%). Baseline composite PsAMRIS score was 11.6±12.8 and baseline PsAMRIS synovitis score was 3.7±3.3. Baseline ultrasound synovial hypertrophy and Doppler activity were 6.2±4.5 and 3.5±4.0, respectively. Specific MRI and ultrasound scores were significantly correlated with DAS28 and DAPSA at baseline. Clinical disease activity parameters significantly improved at follow up (DAS28: 2.94±0.95, p<0.001; DAPSA: 8.8±5.8, p<0.001). PsAMRIS synovitis score (2.5±2.4) as well as composite PsAMRIS score (8.8±10.0) decreased longitudinally with secukinumab treatment (p=0.034 and p=0.039, respectively). There was no progression in erosion or proliferation scores between baseline and follow-up through MRI and HRpQCT imaging. Synovial hypertrophy and Doppler activity in ultrasound also significantly improved with secukinumab treatment (2.3±3.5; p=0.009 and 1.8±2.7; p=0.003, respectively). A significant percentage of patients reaching minimal disease activity showed residual signs of synovitis in the MRI and US (66% and 50%, respectively).

Conclusion:

Secukinumab significantly improves MRI and ultrasound signs of joint inflammation in patients with PsA. No progression in articular damage or osteo-proliferation was observed.


Disclosure: E. Kampylafka, None; I. Oliveira, None; C. Linz, None; V. Lerchen, None; M. Englbrecht, None; M. Sticherling, None; A. Kleyer, None; J. Rech, None; G. Schett, None; A. J. Hueber, None.

To cite this abstract in AMA style:

Kampylafka E, Oliveira I, Linz C, Lerchen V, Englbrecht M, Sticherling M, Kleyer A, Rech J, Schett G, Hueber AJ. Improvement of Joint Inflammation As Assessed By MRI and Power Doppler Ultrasound (PDUS) in an Open Label Study in Patients with Active Psoriatic Arthritis Treated with Secukinumab. [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/improvement-of-joint-inflammation-as-assessed-by-mri-and-power-doppler-ultrasound-pdus-in-an-open-label-study-in-patients-with-active-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvement-of-joint-inflammation-as-assessed-by-mri-and-power-doppler-ultrasound-pdus-in-an-open-label-study-in-patients-with-active-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology